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-Prostanoids are local hormones formed from arachidonic acid that coordinate responses to circulating hormones which elicit prostanoid synthesis. For example, in the kidney, prostaglandin (PG) E2 synthesized by collecting tubule epithelia in response to arginine vasopressin (AVP) acts on the parent collecting tubule as well as the neighboring thick limb to modulate NaCl and water reabsorption occurring in response to AVP. Studies performed over the last 15 years have defined the major cellular and subcellular sites of PG synthesis in the kidney. In addition, it is now recognized that the multiple cellular actions of prostanoids in the kidney are mediated through receptors coupled to guanine nucleotide regulatory proteins. The goal of this review is to summarize recent biochemical and molecular biological studies on prostanoid biosynthetic enzymes and on prostanoid receptors. The major topics to be addressed are 1) phospholipid precursors of arachidonate, 2) membrane-associated and cytosolic phospholipase A+, 3) PG endoperoxide (PGH) synthase isozymes, 4) thromboxane A (TxA) synthase, and 5) TxA/ PGH and PGE receptors. phospholipase A,; phospholipids; prostaglandins; thromboxanes; prostanoid receptors; adenosinetriphosphatase; guanine nucleotide regulatory proteins; prostaglandin endoperoxide synthase; cyclooxygenase; thromboxane A synthase; thromboxane A/prostaglandin endoperoxide receptor PROSTANOIDS~ are formed via the pathway diagrammed in Fig. 1 . This process can be viewed as occurring in the following three stages: 1) hormone-activated mobilization of esterified arachidonate from precursor lipid(s) through the action of one or more lipases; 2) conversion of arachidonate to the prostaglandin (PG) endoperoxide (PGH) Hz mediated by PGH synthases; and 3) cellspecific isomerization or reduction of PGH2 by specific synthases (isomerases) or reductases to the major biologically active prostanoids PGD2, PGE2, PGFB,, prostacyclin (PG12), or thromboxane AZ (TxA,) (87). Following their intracellular synthesis, prostanoids exit the cell, probably via facilitated diffusion (49, 81) . After exiting the cell, prostanoids act on the parent cell and/or neighboring cells in an autocrine and/or paracrine fashion through specific G protein-linked prostanoid receptors to stimulate or inhibit changes in the levels of second messengers (82). In a broad context, prostanoids can be looked upon as local hormones which serve to coordinate responses to circulating hormones that elicit prostanoid synthesis. For example, PGE2 synthesized by collecting tubule epithelia in response to arginine vasopressin (AVP) (41) acts on parent collecting tubule cells to modulate the antidiuretic effect of AVP and on neighboring thick limb cells to modulate NaCl reabsorption necessary for antidiuresis (82). The goal of this review is to summarize information on prostanoid biosynthetic enzymes and on prostanoid receptors that has become available from biochemical and molecular biological studies published since 1988. Accordingly, I will emphasize recent studies on phospholipid turnover, phospholipase A2 (PLAB), PGH synthase, TxA synthase, and TxA/PGH and PGE receptors.
LIPID PRECURSORS OF PROSTANOIDS
l Prostanoids are defined here as all products of the cyclooxygenase pathway for arachidonic acid metabolism (Fig. 1 ). The two other major pathways of the arachidonate cascade are the lipoxygenase pathway, which leads to the production of hydroxy acids and leukotrienes (see Ref. 101 for a recent review), and the epoxygenase pathway, which leads to the formation of epoxy fatty acids and dihydroxy fatty acids (see Ref. 55 for a recent review).
It is widely believed that prostanoids are derived from arachidonate, which is hydrolyzed from membrane phospholipids through the action of PLA2. In fact, the identity of the lipid(s) that is the immediate biosynthetic precursor of prostanoids has not been established. Simple cell labeling studies with rad ioactiv te arachidon .ate do not provide a definitive answer to the prostanoid precursor question because of the complex manner in which arachidonate groups are shuttled among various phospholipids when cells are activated by hormones to synthesize prostanoids. A .lthough the appropriate studies necessary to define the lipid precursor of prosta .noids have not been reported, related work has been performed to define the lipid precursor of a member of the leukotriene (LT) group F182 EDITORIAL I 1 of eicosanoids,l specifically LTB*. I will outline the experimental approach used in this latter case as an example of what needs to be done to identify the prostanoid precursor lipid(s). When isolated cells are incubated with small amounts of exogenous radioactive arachidonate, different classes of lipids become radiolabeled at different rates (4, 7, 8, 22, 79) . Two of the major diacyl glycerophospholipids, phosphatidylinositol (PI) and phosphatidylcholine (PC), are labeled very rapidly (within minutes), whereas the other major diacyl phospholipid, phosphatidylethanolamine (PE), is labeled much more slowly (within hours). Several investigators have taken advantage of this sequential labeling phenomenon, in combination with the nonuniform distribution of arachidonoyl groups in different lipid classes, to differentially radiolabel arachidonate-containing lipid classes in mast cells and neutrophils (4, 7, 8, 22) . In the case of neutrophils, the specific radioactivity of LTB4 formed upon short-term stimulation of these cells with the Ca2+ ionophore A23187 was then determined (7). The specific activity of newly formed LTB4 was found to be the same as that of the arachidonoyl group present in a 1-alkyl-2-acyl-PC (i.e., l-0-alkyl-2-arachidonoyl-sn-glycerophosphocholine) but different from that of the specific activity of radiolabeled, esterified arachidonate present in all other classes of phospholipids and triglycerides. This finding indicates that in neutrophils, LTB4 is synthesized from arachidonate derived from 1-0-alkyl-2-arachidonoyl-sn-glycerophosphocholine.
In the case of the kidney, an obvious cell system that could be used for investigating the lipid precursor of prostanoids by differential labeling techniques would be rabbit collecting tubule cells, because collecting tubules synthesize mainly prostanoids and not other eicosanoid products (29) . A more generic cell type that is also likely to be amenable to the differential labeling approach is the Swiss mouse 3T3 fibroblast. Furthermore, as discussed below, Swiss mouse 3T3 cells can express both PGH synthase-1 and PGH synthase-2 (21), and it certainly would be of interest to determine whether the arachidonate used by each PGH synthase isozyme comes from the same lipid pool.
As noted above, the dogma is that the arachidonic acid used for prostanoid formation is derived from intracellular membrane phospholipids (15, 16). However, there have been intriguing reports indicating that other lipids or lipoproteins can provide arachidonate for prostanoid biosynthesis. For example, Habenicht et al. (32) found that arachidonate can be delivered to Swiss mouse 3T3 cells via the cholesterol esters or phospholipids of lowdensity lipoprotein, which are endocytosed, hydrolyzed, and used as prostanoid precursors (Fig. 1) . Another potential source of arachidonate is the triglyceride pool found in some cells (Fig. 1) . The issue of lipid body triglycerides as a potential source of arachidonate for prostanoid synthesis is currently being investigated by Wellner et al. (98) Table 1 ).
discussion that arachidonate is derived from the SW22 position of intracellular phospholipids, then there are three pathways that can provide arachidonate (Fig. 2) . One involves sequential degradation of PI3 (or PC or PE) via a sequence of reactions beginning with phospholipase C (64)4 and followed by diglyceride lipase and monoglyceride lipase (3, 31, 64) . The second pathway involves an initial conversion of PE or PC to phosphatidic acid catalyzed by a phospholipase D followed by formation of diglyceride and monoglyceride ( Fig. 2 ; see Refs. 3, 5, 31). Finally, a third pathway involves a direct action of a PLA2 on a phospholipid that, depending on the PLA,, could include 1,2-diacyl-or 1-0-alkyl-2-acyl-PI, PE, or PC (Fig. 2) . In blood platelets, as much as 50% of the arachidonate that is mobilized in response to activation of platelets with thrombin appears to derive from 1,2-diacyl-PI via the phospholipase C pathway with the re-2 The designation sn refers to the stereospecifically numbered nomenclature system. Arachidonate is only found esterified at the sn-2 position of glycerophospholipids.
3 PI, but not phosphatidylinositol phosphate(s), is present in sufficient abundance to account for arachidonate release.
4 It should be reemphasized that defining lipid sources of released arachidonate does not define the source of the arachidonate used for prostanoid synthesis. For example, platelet cells synthesize both prostanoid and lipoxygenase products. It is not clear whether arachidonate mobilized from PI via the phospholipase C/glyceride lipase pathway or arachidonate mobilized by the action of PLA2 is used for the synthesis of TxA2 via the cyclooxygenase pathway or for the synthesis of 12-hydroperoxyeicosatetraenoic acid via the 1%lipoxygenase pathway.
mainder coming from other phospholipids via the action of PLA2 pathway(s) (64).* In other cells, most of the arachidonate probably arises directly or indirectly from PI and/or PC via actions of PLA2 (4, 7, 16, 22, 90, 93) . Further difficulties in resolving which lipases are involved in arachidonate release arise from the fact that there are multiple forms of PLA2 and that there are no highly specific inhibitors for any of these enzymes. During the last three or four years, a number of investigators interested in arachidonate release have concentrated on characterizing PLA,s. Table 1 summarizes the properties of known PLA+.
Secretory, pancreatic type I PLA2. The secretory, pancreatic type I PLA2 has been isolated from human and bovine pancreas; this PLAZ is secreted as a proenzyme, and cleavage of a heptapeptide from the NH,-terminal produces an active enzyme with 124 amino acids and a mol wt of -14,000 (5, 96). Mammalian secretory type I PLA,s are closely related phylogenetically to cobra venom enzymes (14). Type I PLA2s contain seven disulfide linkages and are characterized by a cysteine at residue 11. These PLA2s are inactivated by conditions (i.e., high concentrations of thiols) that reduce their disulfide bonds. Pancreatic type I PLAz has an alkaline pH optimum and requires >l mM Ca2+ for activity. The enzyme shows no specificity toward the acyl group at the sn-2 position, and it does not discriminate between PE and PC. There is no evidence for a type I PLAz in kidney. (99), and liver (I), and their sequences have been determined. Type II PLA,s have 124 amino acids and a mol wt of -14,000. Nonpancreatic, type II PLA2s are also similar to the pancreatic, type I enzymes in having seven disulfide bonds; however, nonpancreatic, type II PLA2s are not produced as proenzymes, and they lack a cysteine at residue 11. The nonpancreatic, type II enzymes have alkaline pH optima and require >l mM Ca 2+ for activity. These enzymes show no specificity toward the acyl group at the sn-2 position and do not discriminate appreciably between PC and PE It is somewhat misleading to refer to the nonpancreatic, type II PLA, as a "secretory" form of the enzyme. For example, only a portion of this enzyme is secreted by platelets following platelet activation (44) . In addition, many of the membrane-associated forms of PLA2 found in mammalian cells appear to be type II PLA2s. One example is the liver mitochondrial PLA2 (1). In kidney, Nakamura et al. (61) have documented the presence of both microsomal and mitochondrial enzymes with mol wt of -14,000 which have catalytic properties resembling those of type II PLA2s. In tissues, including kidney, where type II PLA2s are found associated with internal membrane fractions, their activities can be solubilized by incubation of the membranes with high salt (e.g., 1 M KCl). This is a defining property of peripheral membrane proteins that are bound to membranes through noncovalent ionic interactions.
Although no relationship between type II PLA2s and mobilization of arachidonate for prostanoid synthesis has been established, Dennis and co-workers have demonstrated that in the P388D1 macrophage line, manoalide an*d its analogues (70) enzyme is inhibited by low concentrations of arachidonic acid but not saturated or monounsaturated fatty acids (52). In mesangial cells, a type II PLA2 is induced by interleukin-lcu, and induction of this PLA2 is associated with increased prostanoid synthesis (63).
Cytosolic PLA2. Three types of cytosolic (c) PLA2s have been isolated and characterized. Two of these types of cPLA2s are unusual in that they do not require Ca2+ for activity (24, 26) . One of these enzymes (that from myocardial tissue) appears to be activated during ischemia and to be specific for 1-O-alkyl-and 1-O-alk-1'-enyl phospholipids (24, (34) (35) (36) . This enzyme, which is present in both cytosolic and membrane-associated forms, is activated during cardiac ischemia. Although Nakamura et al. (61) have provided evidence for activation of membraneassociated PLA2 activities during renal ischemia, there are no reports of Ca2+ -independent PLA2 activities in kidney.
The PLA2 that has received the most attention during the past few years has been a large (110 kDa) cytosolic protein that undergoes a Ca"+-dependent activation. An enzyme of this type has been isolated from kidney (31) , is present in renal mesangial cells (30), and is activated by AVP (30) and epidermal growth factor (6). The cPLA2 of kidney is activated and becomes reversibly associated with membranes at relatively low concentrations of Ca2+ (ca. 500 nM) known to be present intracellularly following activation of Ca2+ mobilization pathways. Importantly, the kidney cPLA2 exhibits specificity toward phospholipids containing arachidonate at the sn-2 position (31). Based on these properties, this cPLA, is an attractive candidate as the enzyme directly involved in mobilization of arachidonic acid which plays a role in signaling. Thus this cPLA2 may be involved in releasing arachidonate for prostanoid biosynthesis; alternatively or additionally, this cPLA2 may provide substrate for the synthesis of other eicosanoids such as those of the epoxygenase pathways (23). Another possibility is that the newly released arachidonate itself plays a role in signaling The cPLA, is the major form of PLA, in kidney extracts (61). It is likely that this renal cPLA, is the same as or closely related to the cPLA,s that have been purified to homogeneity from U937 cells (11,45) and RAW 264.7 cells (50). The cloning, sequencing, and expression of cDNAs for cPLA,s from human U937 cells (10, 73) and murine RAW 264.7 cells (10) have also been described. In all cases, the cDNAs encode an enzyme having a predicted molecular mass of 85.5 kDa (although the subunit mol mass determined from sodium dodecyl sulfate-polyacrylamide gel electrophoresis is 110 kDa). An NH,-terminal 140-amino acid peptide derived from the cPLA, of U937 cells has been shown to undergo a reversible, Ca2+-dependent binding to membranes. Apparently, this is the biochemical basis for its association with membranes upon Ca2+ mobilization.
Importantly, the cPLA, from U937 cells is found to have specificity toward membrane phospholipids with arachidonate at the sn-2 position. Interestingly, when examined at saturating substrate con-centrations, the cPLA, from RAW 264.7 cells also exhib-its a Ca2+-independent lysophospholipase (PLAJ activ-ity that is two times greater than its Ca2+-dependent cPLA, activity (50); this raises the possibility that, in hydrolyzing phospholipids, this enzyme can cleave the acyl groups sequentially from the sn-2 and sn-1 positions. The regulation of this enzyme by phosphorylation is currently under investigation. cPLA,s are almost certainly involved in hormone-induced eicosanoid biosynthesis in kidney, but a key question is whether these cPLA,s are involved with mobilization of arachidonate destined for the cyclooxygenase, lipoxygenase, and/or epoxygenase pathways.
PGH SYNTHASE ISOZYMES
The second step in prostanoid biosynthesis is the conversion of newly mobilized arachidonate to PGH,; these reactions are both catalyzed by the same enzyme, i.e., PGH synthase (Fig. 2) . During the past year, it has become apparent that there are two PGH synthase isozymes called PGH synthase-1 and -2. Figure 3 compares the deduced amino acid sequences of murine PGH synthases-1 and -2. PGH synthase-1 refers to the enzyme that was originally purified from ovine and bovine vesicular glands and platelets (see Ref. 87 for a recent review). cDNAs coding for PGH synthase-1 have been cloned from murine (17), human (25,104), and ovine sources (19, 57, 103) . PGH synthase-1 has a signal peptide and, following cleavage of the signal peptide (between amino acid residues 26 and 27 in the case of murine PGH synthase-1), contains 576 amino acids and has a mol wt of 65,500. The deduced amino acid sequences of PGH synthases-1 from sheep, human, and mouse are -90% identical at the amino acid level, with the major differences being found in the signal peptide and the 12 amino acids immediately preceding an endoplasmic reticulum retention signal at the COOH-terminal.
PGH synthase-2 was originally isolated as a v-src-inducible gene product in chicken fibroblasts (77, 100) and as a phorbol ester-inducible immediate early gene product called TISlO by murine 3T3 cells (47). Murine PGH synthase-2 has recently been expressed in vitro and has been shown to exhibit both the cyclooxygenase and peroxidase activities characteristic of PGH synthase-1 (48). PGH synthase-2 differs significantly from PGH synthase-1 at positions prior to amino acid residue 30; fully processed PGH synthase-2 has the NHZ-terminal sequence ANPCC corresponding to cleavage of 17 amino acids from the NH2-terminal of the deduced sequence ( Fig. 3 ; Ref. 80). PGH synthase-2 contains an l&amino acid insert very near the COOH-terminal of the enzyme, which is an insert that is not present in PGH synthase-1. The remainder of the sequence of PGH synthase-2 is quite similar to that of PGH synthase-1 (ca. 75% identity). Moreover, as discussed in more detail below, those residues that have been identified as important in the catalytic functions of PGH synthase-1 are all conserved in the PGH synthase-2 (Fig. 3) . Finally, the COOH-terminal TEL sequence, which may be responsible for retaining the protein in the endoplasmic reticulum (66, 71), is conserved. The functional consequences of the differences in primary structures between PGH synthases-1 and -2 are only beginning to be explored using chimeric constructs containing domains from PGH synthases-1 and -2.
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Tissue distribution of PGH synthase isozymes. PGH synthase-1 mRNA is present in many cell lines and in extracts of virtually all mammalian tissues. In contrast, Northern "zoo" blots have indicated that PGH synthase-2 mRNA is detectable in prostate, brain, testis, and lung, but it is in very low or undetectable abundance in kidney and most other major organs (77); with the exception of Rat-l cells and mitogen-stimulated mouse 3T3 fibroblasts, common cell lines lack appreciable PGH synthase-2 mRNA (48).
Renal compartmentation of PGH synthase isozymes. Immunohistochemical localization of PGH synthase in kidneys has been performed using polyclonal and monoclonal antibodies generated against ovine PGH synthase-1 (81, 83). Despite similarities between the structures of PGH synthases-1 and -2, the antibodies used for the immunocytochemistry show little or no cross-reactivity with PGH synthase-2. Thus the major renal cells containing immunoreactive PGH synthase (i.e., collecting tubule epithelia, vascular endothelial cells, interstitial cells, and thin limb) express mainly PGH synthase-I? As discussed below, PGH synthase-2 appears to be dramatically upregulated in situations associated with increased cell replication or differentiation. Thus this isozyme might not be expected to be present in abundance in kidney, except under conditions of inflammation and/or associated tissue repair such as seen with the hydronephrotic kidney model (59, 65, 84) .
Factors that regulate expression of PGH synthase-1 and -2 genes. In Swiss mouse 3T3 cells, mRNA levels of both genes are increased by serum and growth factors, 12-0-tetradecanoylphorbol-13.acetate, and adenosine 3',5'-cyclic monophosphate (CAMP) (18, 47, 51, 77) . However, PGH synthase-2 mRNA levels are upregulated much more dramatically than PGH synthase-1 mRNA levels, and the temporal order of expression of the two genes is also different. In serum-stimulated quiescent 3T3 cells, PGH synthase-2 mRNA increases dramatically from undetectable levels within as little as 30 min, peaking at l-3 h after stimulation and then rapidly declining (77). Serum-induced changes in the levels of PGH synthase-1 mRNA in 3T3 cells involve two-to threefold increases in mRNA levels that occur only 3-4 h poststimulation but which remain elevated 6-8 h after stimulation (18, 47, 51) . Serum treatment of rat renal mesangial cells has also been shown to stimulate PGH synthase-1 gene expression, apparently via a protein kinase C-dependent mechanism (78); it is not known whether PGH synthase-2 mRNA levels are also affected in mesangial cells. Interleukin-lar stimulates, whereas acidic fibroblast growth factor-l inhibits, the expression of PGH synthase-1 in human umbilical cord endothelial cells (39). Human chorionic gonadotropin stimulates the expression of PGH synthase-2 in rat ovarian follicles in association with ovulation (80) .
Structure of genes for PGH synthases-1 and -2. The intron/exon structures of the murine (43) and human (104) PGH synthase-1 genes and the murine PGH synthase-2 gene (21) are illustrated in Fig. 4 . The PGH synthase-1 gene is 22 kb and consists of 11 exons. The intron/exon structures of the human and murine PGH synthase-1 genes are virtually identical (43, 104). The murine PGH synthase-2 gene is much smaller (ca. 8 kb), but, interestingly, the locations of the intron/exon boundaries are the same except for the first exon (47); that is, the introns present in the gene for murine PGH synthase-2 are much smaller than those in PGH synthase-1 (Fig. 4) .
The nucleotide sequences of the 5'-end of the genes for PGH synthases-1 and -2 have been determined (21, 43) ; the transcriptional start sites for both genes have also been defined. There are numerous consensus response elements present in the 5'flanking regions of each gene. For example, there are three AP-l-like elements (for the binding of fos/jun dimers) in the 5'-flanking region of the PGH synthase-1 gene; there is also a putative negative glucocorticoid response element neighboring an AP-1 site. There is no TATA box. The functional relevance of these putative response elements has yet to be tested. A region containing -1 kb upstream of the transcriptional start site of murine PGH synthase-2 has been sequenced and shown to contain AP-1 and SP-1 sites and a putative TATA box. When this upstream regulatory region of the PGH synthase-2 gene is coupled to a luciferase reporter gene and transfected into NIH 3T3 cells, luciferase activity is induced in response to both serum and phorbol ester treatments (21). Curiously, although it has been established that serum will induce the expression of PGH synthase-2, there are no obvious serum response elements in the V-end of the gene. One recent and very important observation is that dexamethasone will inhibit the induction of PGH synthase-2 by phorbol esters in Swiss 31'3 cells (48).
PGH synthase structure/function relationships. PGH synthases-1 and -2 both catalyze two reactions ( Fig. 1;  Ref. 87 ). The first is the cyclooxygenase reaction in which arachidonate is converted to PGG,; no net oxidationreduction occurs in this reaction. The second reaction is a peroxidase reaction involving a net two-electron reduction of the 15hydroperoxyl group of PGGz to the 15 hydroxyl group of PGH2. There is compelling evidence that these two reactions occur at distinct but neighboring catalytic sites. For example, treatment of PGH synthase-1 with indomethacin (58), aspirin (95), or fatty acid analogues (54), which act as competitive inhibitors of arachidonate binding, blocks the cyclooxygenase activity without affecting the peroxidase activity. In contrast, mutants of PGH synthase-1 have been prepared that lack detectable peroxidase activity but express cyclooxygenase activity (75).
Recently, we proposed a two-site model for the actions of PGH synthase-1 (Fig. 5; Refs. 75,86 ). This same model holds for PGH synthase-2. Briefly, peroxides such as PGG2 are envisioned to bind the heme group at the peroxidase active site. The peroxide then undergoes a twoelectron reduction to an alcohol with concomitant oxidation of the heme group. The heme group can subsequently undergo two sequential one-electron reductions regenerating ground state heme, although the electron donor functioning in vivo has not been identified.
There is spectral evidence suggesting that the heme group is bound to PGH synthase-1 via imidazole groups of two histidine residues (see Ref. 87 for review). His30g appears to be the axial heme ligand, whereas it is likely that His388 (Fig. 5) or His207 is the distal heme ligand (75). Shown in Fig. 5 , located between the peroxide (peroxidase) and arachidonic acid (cyclooxygenase) binding sites, is the side chain of Tyr385. Tyr3@j is essential for cyclooxygenase but not peroxidase activity (74, 85). There is evidence that a tyrosyl radical is formed when Fig. 3 ) differs by 2 residues, because the deduced amino acid sequence of ovine PGH synthase-1 contains 2 fewer amino acids than murine PGH synthase-1.
PGH synthase is incubated with PGG2, and it has been proposed that this radical initiates the cyclooxygenase reaction by abstracting the 13-pros hydrogen from arachidonate (20). Tyr385 is an obvious candidate for this role.
Ser530 is the residue whose side chain is acetylated when PGH synthase is inactivated by aspirin (Fig. 5) . Aspirin is the only nonsteroidal anti-inflammatory drug (NSAID) that causes covalent modification of PGH synthase. Replacing Ser530 with an alanine that lacks the hydroxyl side chain produces a mutant PGH synthase which is fully active catalytically but refractory to irreversible inactivation by aspirin (although it is reversibly inhibited by aspirin) (17). This finding indicates that the Ser530 hydroxyl group is not important for catalysis and suggests that acetylation of Ser530 by aspirin places a bulky group at this position which interferes with arachidonate binding to the cyclooxygenase active site. Subsequent studies have confirmed this concept (76); for example, replacement of Ser530 with asparagine or leucine, which are roughly isosteric with an acetylated Ser530, yields mutant PGH synthases-1, which lack cyclooxygenase but retain peroxidase activity.
Pharmacology of PGH synthase-1 vs. PGH synthase-2.
PGH synthase is the target site for most NSAIDs. There are reports of differences in the tissue specificities and pharmacological effects of various NSAIDs. For example, sulindac is one NSAID that can be used in patients with chronic glomerular disease (9). More recently, Holtzman et al. (40) have provided evidence that acetylation of ovine PGH synthase-2 with aspirin produces a protein which forms 15-hydroperoxyeicosatetraenoic acid instead of prostanoid products. Clearly, it is of considerable interest to determine whether PGH synthases-1 and -2 exhibit different specificities toward different NSAIDs and whether these differences underlie the unique pharmacological profiles of different NSAIDs. Directcomparisons of murine PGH synthases-1 and -2 are now possible using in vitro expression systems. Preliminary evidence suggests that there are 2-to 50-fold differences in the Ki values between PGH synthases-1 and -2 for common NSAIDs (E. A. Meade, W. L. Smith, and D. L. Dewitt, unpublished results) . It will be of interest to develop corresponding expression systems for measuring the interactions of NSAIDs with the human PGH synthase isoforms (25) with the aim of identifying or developing isozyme-specific NSAIDs.
METABOLISM
OF PGH,: PGD, PGE, PGF, PGI, AND TXA SYNTHASES After the biosynthesis of PGHB, this endoperoxide is converted to one of a series of possible prostanoid products (Fig. 1) . In general this process is cell specific with differentiated cells producing only one of the major prostanoids in abundance (81, 87 GSH-S-transferase activity. Several proteins have also been identified that exhibit GSH-dependent PGE synthase activity, but it has not been established whether any one of these proteins actually functions in vivo to catalyze PGE2 synthesis. For example, a monoclonal antibody prepared against a 17.5kDa PGE synthase from ovine vesicular gland failed to interact with any proteins present in renal collecting tubule cells, although these cells do exhibit appreciable PGE synthase activity (87).
PGF2, is formed through a two-electron reduction of PGH2. A PGF synthase that catalyzes this reaction using NADPH as an electron donor has been purified from several sources, and its primary structure has been determined by Hayaishi and co-workers (46). A role for this protein lished.
in PGF,, synthesis in vivo has not been estabTxA2 is synthesized by platelets and neutrophils at sites of vascular injury and in association with various immune reactions affecting the kidney (56, 69, 72) . The enzyme catalyzing the conversion of PGHz to TxA2 is TxA synthase (Fig. 1) . Work performed in the mid 1980s predicted that both TxA synthase (33) and prostacyclin synthase (28) would be members of the cytochrome P-450 family. The recent cloning and sequencing of TxA synthases bears out this prediction.
cDNAs coding for TxA synthases have now been isolated from human platelet (102) and human lung (67) cDNA libraries. A longer cDNA found in both platelets and lung has 533 amino acids (60 kDa) and contains the conserved cysteine that serves as the axial heme ligand in all cytochromes P-450. This longer cDNA species is designated TxA synthase I. The overall homology is closest to that of the cytochrome P-450 family III (ca. 35%). Another, shorter cDNA that is likely a splice variant of TxA synthase I has been designated TxA synthase II; however, TxA synthase II lacks the region containing the conserved cysteine characteristic of cytochromes P-450. Neither TxA synthase cDNA has as yet been expressed as a functional protein. responses that have been characterized most extensively at the cellular and molecular levels are the effects of PGE2 on the collecting tubule and thick ascending limb and the effects of TxA2/PGH2 analogues on renal mesangial cells. In cortical collecting tubule cells and cortical and medullary thick limb cells, PGEB has been shown to act through pharmacologically distinct stimulatory (EP2) and inhibitory (EP3) PGE receptors to stimulate and inhibit CAMP formation, respectively ( Fig. 6 ; Refs. 62, 88, and 89). PGE2, presumably acting via an EPl receptor, has also been demonstrated to stimulate Ca2+ mobilization and protein kinase C activity in the rabbit collecting tubule ( Fig. 6; Ref. 37 ). More recently, PGE2 was found to inhibit Na+-K+-ATPase activity and ouabain binding in MDCK cells (12); this latter effect appears to be G protein mediated. The effects of PGE2 on CAMP formation and on protein kinase C (via stimulation of diacylglycerol formation) appear to be involved in regulating the responses of the collecting tubule and thick ascending limb to AVP (2, 82, 92) .
TxA2/PGH2 analogues act on mesangial cells to cause contraction (56). This effect is probably mediated via a TxA/PGH receptor coupled to Ca2+ mobilization in a manner functionally analogous to an EPl PGE receptor (Fig. 6) .
Binding of prostanoids such as PGE2 to membrane and solubilized membrane preparations from kidney is influenced by guanine nucleotide analogues (89, 97). Thus it has been suspected that prostanoids exert their effects through G protein-linked receptors. During the last year, direct evidence for this concept has emerged from the work of Narumiya and colleagues (38, 91). Hirata et al. (38) cloned a functional TxA/PGH receptor from a human placenta cDNA library, and Sugimoto et al. (91) cloned a functional EP3 PGE receptor from a mouse lung cDNA library (Fig. 7) . In each case, the sequences of the receptors encoded proteins predicted to be members of the G protein-linked receptor family having seven membrane-spanning domains. 
